病例报告：肺腺癌中ALK D1225N错义突变对酪氨酸激酶抑制剂有反应。
Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors.
发表日期：2023
作者：
Jianxin Chen, Junhui Wang
来源：
Frontiers in Pharmacology
摘要：
ALK基因的有义突变通常被认为是非驱动突变，没有病理学意义，因此缺乏有效的靶向药物。ALK有义突变的患者的标准治疗选择通常是化疗，可以选择加用抗血管生成药物，但通常效果不佳。在此，我们报道了一个携带ALK D1225N中唯一有义突变的转移性肺腺癌患者的病例，该患者对两种ALK酪氨酸激酶抑制剂（TKIs），即克唑替尼和恩沙替尼，有良好反应。我们的病例强调了携带D1225N突变的非小细胞肺癌（NSCLC）患者可能从ALK-TKIs中受益，因此，ALK-TKIs应被考虑作为进一步治疗的候选药物。版权 © 2023 陈和王。
ALK gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with ALK missense mutations is chemotherapy with or without antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case of a patient with metastatic lung adenocarcinoma harboring the only missense mutation in ALK D1225N responding to two ALK-tyrosine kinase inhibitors (TKIs), namely, crizotinib and ensartinib. Our case highlights that non-small cell lung cancer (NSCLC) patients harboring the D1225N mutation may benefit from ALK-TKIs, and therefore, ALK-TKIs should be considered candidates for further line treatment.Copyright © 2023 Chen and Wang.